Mounjaro®
Starting from £179.99/mo
Start journey Learn moreNo — Wegovy is a once-weekly injection, not a monthly one. Each pre-filled pen contains four doses and is used one dose at a time, every seven days, on a day that suits you. The monthly packaging is where the confusion tends to come from. Because each pen lasts roughly four weeks, some people read "one pen" as "one jab" — that's the mix-up this page unpicks. Wegovy (semaglutide) is a prescription-only medicine; a prescriber assesses whether it's clinically appropriate before treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The most common source of this confusion is the way Wegovy is supplied. You receive a single KwikPen, and it covers roughly a month of treatment, so at a glance it can look like a once-monthly medicine. It isn't. The pen is designed to deliver four separate weekly doses, each dialled and injected seven days apart. Thinking of it as a monthly jab and stretching doses out would mean going weeks without semaglutide in your system, which is not how the medicine is studied or licensed to work.
The NHS medicines page for semaglutide is clear that Wegovy is a once-weekly injection. If you've seen the term "monthly" used on a website selling weight-loss medication, treat that as a red flag about the source rather than a fact about the medicine.
A quick practical note: once you've picked your injection day, it's worth anchoring it to something fixed in your week. A lot of people pick Sunday evening, or the same weekday morning. That consistency is easier to maintain than trying to count seven days each time.
Wegovy's schedule is gradual by design. Treatment opens at 0.25 mg (a dose chosen to settle your system, not yet at a therapeutic level) and the prescriber typically moves through 0.5 mg, 1.0 mg and 1.7 mg before reaching the 2.4 mg maintenance dose, spending around four weeks at each stage. The MHRA also approved a 7.2 mg maintenance dose in January 2026, with a dedicated single-dose pen following in April 2026 for adults with a BMI of 30 or above.
What this means in practice is that your first few months on Wegovy are about adjustment as much as weight loss. Month two looks different from month one; month three is different again. If you're curious about what those early stages typically involve, our page on month two of Wegovy treatment and what tends to happen in month three walk through the clinical picture in more detail.
The STEP 1 trial (published in the New England Journal of Medicine) ran for 68 weeks and found an average weight reduction of around 15% at the 2.4 mg dose. That result reflects consistent weekly dosing across the full period alongside lifestyle changes, not a shortened or interrupted schedule.
This is a question our prescribers hear regularly. Spacing doses out beyond seven days (whether intentionally or because a pen is delayed) is not the same as the studied schedule, and the right course of action depends on how much time has passed. That detail belongs in the Wegovy Patient Information Leaflet and your prescriber's hands, not on an information page. The short version: don't try to guess, and don't double-dose. Contact whoever prescribed your treatment.
The broader point is that Wegovy is a prescription medicine precisely because questions like this require clinical input. If you're wondering whether it's right for you in the first place, our Wegovy overview covers licensing, eligibility, and how semaglutide works, a useful starting point before a consultation. You can also read more about the once-weekly dosing structure if you want a fuller picture of the schedule in practice.
Private Wegovy pricing is quoted per pen, which covers roughly four weeks. That framing can reinforce the "once a month" impression. To be clear: the price you see is for one pen containing four weekly doses, not for a single injection.
Understanding what a monthly cost does and doesn't include is worth doing carefully. Some providers quote a headline pen price and add consultation and prescription fees separately; others include aftercare as an optional extra. On our treatment page, the price shown covers the consultation, prescription, the medicine itself, and next-working-day tracked delivery, no separate fees for those elements. For broader context on how Wegovy pricing works in the UK private market, our buying guide runs through what to look for.
Wegovy's cost is also worth considering alongside alternatives. If you're comparing semaglutide with other licensed options, our comparison of Wegovy and its competitors covers the clinical and practical differences. And if you're early in your research and want a wider view of weight-loss treatment options, that's a good place to take stock.
For a full overview of semaglutide as a medicine (the mechanism, the evidence, the side-effect profile) our semaglutide page pulls the key facts together. When you're ready to find out whether Wegovy is clinically suitable for you, start your free consultation and a GPhC-registered prescriber will review your answers the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.